|
DCF -Bewertung der Lunger Corporation (Lung)
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Pulmonx Corporation (LUNG) Bundle
Entdecken Sie das wahre Potenzial der Pulmonx Corporation (Lung) mit unserem fortschrittlichen DCF -Taschenrechner! Passen Sie die wichtigsten Annahmen an, erkunden Sie verschiedene Szenarien und bewerten Sie, wie sich Änderungen auf die Bewertung der Pulmonx Corporation auswirken - alles innerhalb einer einzigen Excel -Vorlage.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.7 | 48.4 | 53.7 | 68.7 | 83.8 | 106.6 | 135.5 | 172.4 | 219.2 | 278.8 |
| Revenue Growth, % | 0 | 47.91 | 10.84 | 27.98 | 22.01 | 27.18 | 27.18 | 27.18 | 27.18 | 27.18 |
| EBITDA | -28.4 | -46.6 | -56.0 | -55.1 | -57.7 | -92.1 | -117.2 | -149.0 | -189.5 | -241.1 |
| EBITDA, % | -86.88 | -96.29 | -104.34 | -80.22 | -68.87 | -86.45 | -86.45 | -86.45 | -86.45 | -86.45 |
| Depreciation | .4 | 3.2 | 4.0 | 1.9 | 1.5 | 4.2 | 5.4 | 6.8 | 8.7 | 11.1 |
| Depreciation, % | 1.22 | 6.53 | 7.45 | 2.84 | 1.78 | 3.96 | 3.96 | 3.96 | 3.96 | 3.96 |
| EBIT | -28.8 | -49.8 | -60.0 | -57.0 | -59.2 | -94.2 | -119.8 | -152.3 | -193.7 | -246.4 |
| EBIT, % | -88.1 | -102.82 | -111.79 | -83.06 | -70.65 | -88.36 | -88.36 | -88.36 | -88.36 | -88.36 |
| Total Cash | 231.6 | 180.0 | 141.1 | 117.1 | 101.5 | 106.6 | 135.5 | 172.4 | 219.2 | 278.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4.2 | 6.6 | 8.7 | 13.0 | 13.1 | 16.5 | 20.9 | 26.6 | 33.9 | 43.1 |
| Account Receivables, % | 12.92 | 13.55 | 16.17 | 18.96 | 15.66 | 15.45 | 15.45 | 15.45 | 15.45 | 15.45 |
| Inventories | 10.7 | 16.3 | 14.6 | 16.7 | 16.9 | 29.4 | 37.4 | 47.6 | 60.6 | 77.0 |
| Inventories, % | 32.81 | 33.64 | 27.14 | 24.38 | 20.19 | 27.63 | 27.63 | 27.63 | 27.63 | 27.63 |
| Accounts Payable | 1.5 | 1.6 | 1.8 | 1.5 | 3.8 | 3.8 | 4.8 | 6.1 | 7.8 | 9.9 |
| Accounts Payable, % | 4.5 | 3.27 | 3.28 | 2.18 | 4.57 | 3.56 | 3.56 | 3.56 | 3.56 | 3.56 |
| Capital Expenditure | -.9 | -3.7 | -1.3 | -.8 | -1.4 | -3.4 | -4.3 | -5.4 | -6.9 | -8.8 |
| Capital Expenditure, % | -2.78 | -7.58 | -2.46 | -1.18 | -1.73 | -3.14 | -3.14 | -3.14 | -3.14 | -3.14 |
| Tax Rate, % | -0.89455 | -0.89455 | -0.89455 | -0.89455 | -0.89455 | -0.89455 | -0.89455 | -0.89455 | -0.89455 | -0.89455 |
| EBITAT | -29.0 | -50.1 | -60.4 | -57.6 | -59.7 | -94.2 | -119.8 | -152.3 | -193.7 | -246.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -43.0 | -58.4 | -57.9 | -63.2 | -57.6 | -109.2 | -130.1 | -165.5 | -210.4 | -267.6 |
| WACC, % | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 | 6.93 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -703.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -273 | |||||||||
| Terminal Value | -5,537 | |||||||||
| Present Terminal Value | -3,961 | |||||||||
| Enterprise Value | -4,665 | |||||||||
| Net Debt | -14 | |||||||||
| Equity Value | -4,650 | |||||||||
| Diluted Shares Outstanding, MM | 39 | |||||||||
| Equity Value Per Share | -118.89 |
What You Will Get
- Pre-Filled Financial Model: Pulmonx Corporation’s actual data provides accurate DCF valuation.
- Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential metrics.
- Instant Calculations: Real-time updates ensure you see outcomes as you implement changes.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation.
- Customizable and Reusable: Designed for adaptability, allowing repeated application for comprehensive forecasts.
Key Features
- Comprehensive Data: Pulmonx Corporation's historical financial statements and pre-filled projections.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Instantly view Pulmonx's intrinsic value recalculating on demand.
- Visual Data Representation: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the prebuilt Excel template featuring Pulmonx Corporation’s (LUNG) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including Pulmonx Corporation’s intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or create reports.
Why Choose Pulmonx Corporation (LUNG)?
- Innovative Solutions: Cutting-edge technology for lung health improvement.
- Proven Results: Backed by clinical studies demonstrating effectiveness.
- Patient-Centric: Focused on enhancing patient quality of life through advanced treatments.
- Expertise: Developed by a team of industry leaders and medical professionals.
- Accessible Information: Comprehensive resources available for patients and healthcare providers.
Who Should Use This Product?
- Investors: Evaluate Pulmonx Corporation’s (LUNG) market position before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methods and assess financial forecasts for Pulmonx Corporation.
- Startup Founders: Gain insights into how companies like Pulmonx Corporation are valued in the healthcare sector.
- Consultants: Create detailed valuation reports to assist clients in understanding Pulmonx Corporation’s worth.
- Students and Educators: Utilize real-time data from Pulmonx Corporation to explore and teach valuation strategies.
What the Template Contains
- Pre-Filled DCF Model: Pulmonx Corporation’s (LUNG) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Pulmonx Corporation’s (LUNG) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.